There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Celldex Therapeutics Inc. (CLDX) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$1.07, or -3.69%, to $27.95. The Celldex Therapeutics Inc. has recorded 65,032 volume in the after hours trading session. Yahoo Finance discussed the stock recently as it posted Celldex Therapeutics Announces Pricing of Public Offering of Common Stock.
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $29.02 and fluctuated between $31.22 as its day high and $28.91 as its day low. The current market capitalization of Celldex Therapeutics Inc. is $1.37B. A total of 1.3 million shares were traded on the day, compared to an average of 544.51K shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, CLDX has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 1 BUYs and 1 SELLs from insiders. Insiders purchased 16,860 shares during that period but sold 16,860.
In the most recent transaction, KELER TIBOR sold 16,860 shares of CLDX for 36.93 per share on Dec 07. After the transaction, the EXECUTIVE VP & CSO now owns 7,357 company shares.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for CLDX in the last 3 months, the mean price target is $64.00 with high estimates of $80.00 and low estimates of $27.00. In terms of 52-week highs and lows, CLDX has a high of $48.40 and a low of $22.11.
As of this writing, CLDX has an earnings estimate of -$0.68 per share for the current quarter. EPS was calculated based on a consensus of 7 estimates, with a high estimate of -$0.62 per share and a lower estimate of -$0.75. The company reported an EPS of -$0.62 in the last quarter, which was 1.60% higher than expectations of -$0.63.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. CLDX’s latest balance sheet shows that the firm has $408.25M in Cash & Short Term Investments as of fiscal 2021. There were $3.04M in debt and $16.53M in liabilities at the time. Its Book Value Per Share was $5.22, while its Total Shareholder’s Equity was $419.48M.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CLDX is Buy with a score of 4.43.